Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck has made changes in responsibilities for three of its leaders Richard Clark, Kenneth Frazier and Adam Schechter.
Subscribe to our email newsletter
Richard Clark, currently chairman, president and CEO, is expected to continue leading the company as chairman and CEO. Kenneth Frazier, currently president of the Global Human Health worldwide sales and marketing division of Merck, was elected as president by the Merck board of directors, reporting to Mr Clark.
Adam Schechter, who currently leads the Merck’s pharmaceutical business in the US, was elected to succeed Mr Frazier as president of Global Human Health.
Merck said that as company president, Mr Frazier is expected to lead Merck’s three divisions responsible for pharmaceutical and vaccine sales and marketing, research and development, and manufacturing and supply.
Additionally, he will ensure the effective collaboration among these global and interdependent divisions, which is critical to the success of the November 2009 merger of Merck and Schering-Plough and the Merck’s long-term performance.
In addition to Mr Schechter, Willie Deese, president of Merck manufacturing division and Peter Kim, president of Merck research laboratories, will also report to Mr Frazier.
The board has also elected Adam Schechter as president of the company’s Global Human Health division. He currently leads the unit’s US market.
Mr Clark said: “Kenneth Frazier is proven to have deep knowledge about our company and the industry and he has real passion for Merck’s role in saving and improving lives through scientific innovation.
“Merck’s board and I have the utmost confidence in Kenneth Frazier’s ability to help navigate Merck during a time of unprecedented change and enormous opportunity in the global health care industry.
“To that end, leadership development and succession planning are among my top priorities. This change in responsibilities is a logical next step for Kenneth Frazier and demonstrates the confidence the Merck board and I have in him.
“Adam Schechter’s talent and experience make him the ideal choice to lead our worldwide sales and marketing business for pharmaceutical medicines and vaccines. I know we can count on Adam to help Merck deliver against our ambitious goals.”